Cited by 369Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., Perrillo, R. P.·2004·Alimentary Pharmacology & Therapeutics

DOI 10.1111/j.1365-2036.2004.02025.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease. AIM: A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease. METHODS: In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology. RESULTS: Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis. CONCLUSION: Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02025.x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Steatohepatitis
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Metformin
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726

Show all 37 references

Research works printed but not linked: 1

10.1002/hep.1840380427 · DOI

Sorted by citations

Items 201–300 of 366

Review article: the treatment of fatty liver disease associated with the metabolic syndrome
Marchesini, G., Natale, S., Manini, R., & Agostini, F. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02593.x · Cited by 20
A porcine placental extract prevents steatohepatitis by suppressing activation of macrophages and stellate cells in mice
Xu, L., Nagata, N., Nagashimada, M., Zhuge, F., Ni, Y., Chen, G., Kamei, J., Ishikawa, H., Komatsu, Y., Kaneko, S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24587 · Cited by 19
Metformin-attenuated sepsis-induced oxidative damages: a novel role for metformin.
Ghavimi, H., Sheidaei, S., Vaez, H., Zolali, E., Asgharian, P., & Hamishehkar, H. (2018) · Europe PMC (PubMed Central) · doi:10.22038/ijbms.2018.24610.6126 · Cited by 19
Anti-Diabetic Medications for the Pharmacologic Management of NAFLD
Cholankeril, R. T., Patel, V., Perumpail, B. J., Yoo, E. R., Iqbal, U., Sallam, S., Shah, N. D., Kwong, W., Kim, D., & Ahmed, A. (2018) · Diseases · doi:10.3390/diseases6040093 · Cited by 21
The therapy of insulin resistance in other diseases besides type 2 diabetes
Pala, L., Barbaro, V., Dicembrini, I., & Rotella, C. M. (2014) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-014-0139-y · Cited by 18
New treatments for nonalcoholic fatty liver disease
Harrison, S. A. (2006) · Current Gastroenterology Reports · doi:10.1007/s11894-006-0060-2 · Cited by 19
A novel combination of metformin and resveratrol alleviates hepatic steatosis by activating autophagy through the cAMP/AMPK/SIRT1 signaling pathway
Afshari, H., Noori, S., & Zarghi, A. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02520-7 · Cited by 20
A New Endemic of Concomitant Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B
Hanif, H., Khan, M. M., Ali, M. J., Shah, P. A., Satiya, J., Lau, D., & Aslam, A. (2020) · Microorganisms · doi:10.3390/microorganisms8101526 · Cited by 17
[Non-alcoholic fatty liver disease: a new challenge for cardiologists].
Tarquini, R., Lazzeri, C., Boddi, M., Marra, F., Abbate, R., & Gensini, G. F. (2010) · PubMed · Cited by 16
Prevalence of nonalcoholic fatty liver disease in type 2 diabetes mellitus and its relation with insulin resistance in South Gujarat Region
Bhatt, K., Pranav, V., Dipika, Y., Dharmesh, N., Nittala, R., & Arvind, S. (2017) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/0971-9903.202001 · Cited by 16
Medical Management of Chronic Liver Diseases (CLD) in Children (Part II)
El-Shabrawi, M. H. F., & Kamal, N. M. (2011) · Pediatric Drugs · doi:10.2165/11591620-000000000-00000 · Cited by 16
Pharmacological therapy of nonalcoholic steatohepatitis
Hojo, M., & Watanabe, S. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2011.00780.x · Cited by 15
Third Annual World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2006) · Diabetes Care · doi:10.2337/dc06-zb09 · Cited by 16
Deficiency in apolipoprotein A-I ablates the pharmacological effects of metformin on plasma glucose homeostasis and hepatic lipid deposition
Karavia, E. A., Hatziri, A., Kalogeropoulou, C. P., Papachristou, N., Xepapadaki, E., Constantinou, C., Νάτσος, Α., Πετροπούλου, Π.-Ι., Sasson, S., Papachristou, D. J., et al. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.040 · Cited by 15
Effect of essentiale in diabetic subjects with Non - Alcoholic fatty liver
Poongothai, S., Karkuzhali, K., Prakash, G., Sangeetha, T., Saravanan, G., Deepa, R., Gopalakrishnan, S. S., & Mohan, V. (2005) · International Journal of Diabetes in Developing Countries · doi:10.4103/0973-3930.26859 · Cited by 15
Medical Management of Chronic Liver Diseases in Children (Part I)
El-Shabrawi, M. H. F., & Kamal, N. M. (2011) · Pediatric Drugs · doi:10.2165/11591610-000000000-00000 · Cited by 15
Non-alcoholic steatohepatitis
Neuschwander‐Tetri, B. A. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/01.med.0000216959.98385.02 · Cited by 15
Glucagon-like Peptide-1 Improves Fatty Liver and Enhances Thermogenesis in Brown Adipose Tissue via Inhibiting BMP4-Related Signaling Pathway in High-Fat-Diet-Induced Obese Mice
Wang, X., Ma, B., Chen, J., You, H., Sheng, C., Yang, P., & Qu, S. (2021) · International Journal of Endocrinology · doi:10.1155/2021/6620289 · Cited by 16
Effect of Insulin versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes
Lingvay, I., Roe, E. D., Duong, J., Leonard, D. S., & Szczepaniak, L. S. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3182621c5f · Cited by 14
The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis
Zamin, I., de Mattos, Â. A., de Mattos, Â. Z., Coral, G. P., dos Santos, D. E., & Rhoden, C. R. (2010) · Arquivos de Gastroenterologia · doi:10.1590/s0004-28032010000100015 · Cited by 14
Nonalcoholic fatty liver disease: from clinical recognition to treatment
Sevastianos, V., & Hadziyannis, S. J. (2008) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2.1.59 · Cited by 14
ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF ALOGLIPTIN AND METFORMIN HYDROCHLORIDE TABLET DOSAGE FORM BY RP-HPLC METHOD
Kumar, A. P., Aruna, G., Rajasekar, K., & Reddy, P. J. (2013) · Cited by 14
Hepatocellular carcinoma and metabolic syndrome: The times are changing and so should we
Tsoulfas, G. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i29.3842 · Cited by 16
Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome
Tan, S., Vollmar, N., Benson, S., Sowa, J., Bechmann, L. P., Gerken, G., Führer, D., & Canbay, A. E. (2015) · International Journal of Endocrinology · doi:10.1155/2015/254169 · Cited by 12
Potential Approaches to Ameliorate Hepatic Fat Accumulation Seen with MTP Inhibition
Lin, M., Zhao, S., Shen, L., & Xu, D. (2014) · Drug Safety · doi:10.1007/s40264-014-0147-x · Cited by 13
Nonalcoholic steatohepatitis: Pathogenesis and treatment
Park, S. H. (2008) · The Korean Journal of Hepatology · doi:10.3350/kjhep.2008.14.1.12 · Cited by 13
Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis
Satiya, J., Snyder, H. S., Singh, S. P., & Satapathy, S. K. (2021) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-20-247 · Cited by 11
Disease pathways and molecular mechanisms of nonalcoholic steatohepatitis
Wegermann, K., Diehl, A. M., & Moylan, C. A. (2018) · Clinical Liver Disease · doi:10.1002/cld.709 · Cited by 12
Self-citation
Drug-Induced Liver Injury
Bonkovsky, H. L., Jones, D. P., LaBrecque, D. R., & Shedlofsky, S. I. (2006) · Elsevier eBooks · doi:10.1016/b978-1-4160-3258-8.50031-0 · Cited by 12
Mechanisms underlying nonalcoholic steatohepatitis
Abdelmalek, M. F., & Diehl, A. M. (2006) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2006.11.001 · Cited by 12
Self-citation
Hypoglycemic and antihyperglycemic effects of Abelmoschus esculentus and Alchornea cordifolia in normal and alloxan-induced diabetic rats
Nkono, B. L. N. Y., Hamadjida, A., GOUNKAGOU, D., Ntchapda, F., Dongmo, S. S., & Kamtchouing, P. (2024) · Pharmacological Research - Modern Chinese Medicine · doi:10.1016/j.prmcm.2024.100531 · Cited by 11
TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD): A SYSTEMATIC REVIEW
Eslami, L., Merat, S., & Moghadam, S. N. (2009) · Middle East Journal of Digestive Diseases · Cited by 11
Dapagliflozin-Induced Acute-on-Chronic Liver Injury
Levine, J. A., Lo, A. A., Wallia, A., Rogers, M. C., & VanWagner, L. B. (2016) · ACG Case Reports Journal · doi:10.14309/crj.2016.142 · Cited by 11
Liraglutide With Metformin Therapy Ameliorates Hepatic Steatosis and Liver Injury in a Mouse Model of Non-alcoholic Steatohepatitis
Chiu, H., Tsai, S., Tsai, F., Lo, Y., Cheng, C., Liu, T., JHAN, S.-R., Yang, J., & Chiu, Y. (2023) · In Vivo · doi:10.21873/invivo.13178 · Cited by 11
Review: Treatment options for nonalcoholic fatty liver disease
Chitturi, S. (2008) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x08096951 · Cited by 11
Roles of Kupffer Cells in Alcoholic Liver Disease
Takei, Y., Arteel, G. E., Bergheim, I., Lambert, J. C., McMullen, M. R., Nagy, L. E., Enomoto, N., & Sato, N. (2005) · Alcoholism Clinical and Experimental Research · doi:10.1097/01.alc.0000168169.20591.64 · Cited by 11
Pharmacological treatment of non-alcoholic steatohepatitis: The current evidence
Diakou, M., Liberopoulos, E. N., Mikhailidis, D. P., Tsianos, E. V., Burroughs, A. K., & Elisaf, M. (2006) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520601058395 · Cited by 11
Rationale for conducting a randomized trial to examine the efficacy of metformin in improving survival in cirrhosis: Pleiotropic effects hypothesis
Loomba, R. S. (2014) · Hepatology · doi:10.1002/hep.27314 · Cited by 9
Therapy for Nonalcoholic Fatty Liver Disease
Moseley, R. H. (2008) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e31815e4079 · Cited by 9
Alteraciones de la tolerancia a la glucosa y frecuencia de síndrome metabólico en pacientes con enfermedad por hígado graso no alcohólico
Araya, A. V., Valera, J. M., Jorge Contreras, B., Attila Csendes, J., Juan Carlos Díaz, J., Patricio Burdiles, P., Jorge Rojas, C., Fernando Maluenda, G., Gladys Smok, S., & Jaime Poniachik, T. (2006) · Revista médica de Chile · doi:10.4067/s0034-98872006000900002 · Cited by 10
Nonalcoholic Fatty Liver Disease
Palmer, M. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0548-5_10 · Cited by 12
Use of Insulin Sensitizers in NASH
Khashab, M. A., & Chalasani, N. (2007) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2007.07.006 · Cited by 10
Near-infrared emissive cyanine probes for selective visualization of the physiological and pathophysiological modulation of albumin levels
Biswas, B., Dogra, S., Dey, G., Murugan, N. A., Mondal, P., & Ghosh, S. (2022) · Journal of Materials Chemistry B · doi:10.1039/d1tb02613e · Cited by 10
Cisapride decreasing orocecal transit time in patients with nonalcoholic steatohepatitis.
Fu, X., & Jiang, F. Y. (2006) · PubMed · Cited by 9
Update on the Treatments of Non-Alcoholic Fatty Liver Disease (NAFLD)
Quercioli, A., Montecucco, F., & Mach, F. (2009) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x10909040261 · Cited by 10
Non-Alcoholic Fatty Liver Disease
Tan, H., & Chang, J. P. (2010) · Proceedings of Singapore Healthcare · doi:10.1177/201010581001900106 · Cited by 9
Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus
Gentile, S., Guarino, G., Strollo, F., Romano, M., Genovese, S., Masarone, M., & Ceriello, A. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.006 · Cited by 9
Non‐Alcoholic Fatty Liver Disease
Nikolopoulos, A., & Oben, J. A. (2009) · Wiley eBooks · doi:10.1002/9781444322682.ch8 · Cited by 9
Recurrent nonviral liver disease following liver transplantation
Li, K., & Neuberger, J. (2009) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.16 · Cited by 8
Application of proton magnetic resonance spectroscopy and computerized tomography in the diagnosis and treatment of nonalcoholic fatty liver disease
Wang, N., Dong, H., Wei, S., & Lu, F. (2008) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-008-0315-2 · Cited by 8
Practical management of the increasing burden of non-alcoholic fatty liver disease
Mouralidarane, A., Lin, C., Suleyman, N. M., Soeda, J., & Oben, J. A. (2010) · Frontline Gastroenterology · doi:10.1136/fg.2009.000935 · Cited by 8
Obesity as the Omni-Factor for Serious Diseases
Stepanova, Y. V., Loranskaya, I. D., Ministry of Health of Russian Federation, M., Lg, R., Vrachej, T. N. L. T. I. U., Ld, M., & Tsent. Inst. Usover. Vrachej, M. (2019) · Effective Pharmacotherapy · doi:10.33978/2307-3586-2019-15-18-68-77 · Cited by 9
Metformin and the Fate of Fat
Hoek, J. B. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.05.009 · Cited by 8
Nonalcoholic Fatty Liver Disease
Siddiqui, M. S., & Sanyal, A. J. (2015) · Wiley eBooks · doi:10.1002/9781118512074.ch104 · Cited by 8
La diabetes en la cirrosis hepática
García‐Compeán, D., Jáquez-Quintana, J. O., González, J. A., Lavalle-Gonzalez, F. J., Villarreal‐Pérez, J. Z., & Maldonado-Garza, H. J. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.01.012 · Cited by 7
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
Angelico, F., Alessandri, C., Ben, M. D., & Lirussi, F. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005166.pub3 · Cited by 7
Recent advances in the treatment of non-alcoholic fatty liver disease
Mendes, F. D., & Lindor, K. D. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.1.29 · Cited by 7
Non‐Alcoholic Fatty Liver Disease
Ahmed, M. H., & Byrne, C. D. (2011) · Wiley eBooks · doi:10.1002/9781444347319.ch15 · Cited by 8
Nonalcoholic Fatty Liver Disease
Argo, C. K., Henry, Z. H., & Caldwell, S. H. (2017) · Wiley eBooks · doi:10.1002/9781119251316.ch32 · Cited by 7
Current Treatment Options, Including Diet, Exercise, and Medications
Noureddin, M., & Abdelmalek, M. F. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.008 · Cited by 6
Novel treatment strategies for patients with nonalcoholic fatty liver disease
Lam, B. P., & Younossi, Z. M. (2011) · Clinical Investigation · doi:10.4155/cli.10.24 · Cited by 6
Emerging role of nanotechnology in treatment of non-alcoholic fatty liver disease (NAFLD)
Moghtadaie, A., Mahboobi, H., Fatemizadeh, S., & Kamal, M. A. (2023) · EXCLI journal · doi:10.17179/excli2023-6420 · Cited by 6
Nonalcoholic Fatty Liver Disease: Review
Datta, I. K., Rahman, A., Bhuiyan, T. M., & Kabir, M. M. (2012) · BIRDEM Medical Journal · doi:10.3329/birdem.v2i1.12360 · Cited by 6
Complications and Comorbidities of Type 2 Diabetes
Norris, A. W., & Svoren, B. M. (2005) · Pediatric Annals · doi:10.3928/0090-4481-20050901-11 · Cited by 6
Nonalcoholic Fatty Liver Disease
Reid, A. E. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-6189-2.00085-8 · Cited by 6
Effects of obesity and 10 weeks metformin treatment on liver steatosis
Hakkak, R., Rose, S., Spray, B. J., Kozaczek, M., & Korourian, S. (2021) · Biomedical Reports · doi:10.3892/br.2021.1425 · Cited by 6
Esteatohepatitis alcohólica y no alcohólica: ¿quiénes son los pacientes y qué podemos hacer por ellos?
Gallego‐Durán, R., Ampuero, J., Funuyet, J., & Romero‐Gómez, M. (2013) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2013.06.005 · Cited by 6
Current and novel therapies for the treatment of nonalcoholic steatohepatitis
van der Poorten, D., & George, J. (2007) · Hepatology International · doi:10.1007/s12072-007-9011-8 · Cited by 6
Metabolic correlation and management strategies of non-alcoholic fatty liver disease: An Asian Indian perspective
Luthra, A., Nigam, P., & Misra, A. (2007) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.09.005 · Cited by 6
Esteatosis hepática no alcohólica. Puesta al día
Caballería, L., Torán‐Monserrat, P., Llorens, M. A. A., & Pera, G. (2008) · Atención Primaria · doi:10.1157/13125408 · Cited by 6
Non-alcoholic fatty liver disease
Jamali, R., & Jamali, A. (2010) · KAUMS Journal · Cited by 6
Diabetes and Nonalcoholic Fatty Liver Disease
Kantartzis, K., Gastaldelli, A., Magkos, F., & Lavoie, J.-M. (2011) · Experimental Diabetes Research · doi:10.1155/2012/404632 · Cited by 5
Nonalcoholic Fatty Liver Disease
Caldwell, S. H., Argo, C. K., & Al‐Osaimi, A. M. S. (2011) · Wiley eBooks · doi:10.1002/9781119950509.ch32 · Cited by 6
Diverting hepatic lipid fluxes with lifestyles revision and pharmacological interventions as a strategy to tackle steatotic liver disease (SLD) and hepatocellular carcinoma (HCC)
Misceo, D., Mocciaro, G., D’Amore, S., & Vacca, M. (2024) · Nutrition & Metabolism · doi:10.1186/s12986-024-00871-3 · Cited by 6
Stéatopathies métaboliques
Lemoine, M., & Serfaty, L. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.04.006 · Cited by 5
Melatonin alleviates diet-induced steatohepatitis by targeting multiple cell types in the liver to suppress inflammation and fibrosis
Xu, L., Li, H., Zhang, O., Zhang, F., Song, M., Ma, M., Zhao, Y., Ding, R., Li, D., Dong, Z., et al. (2022) · Journal of Molecular Endocrinology · doi:10.1530/jme-22-0075 · Cited by 5
Anti-Inflammatory and Therapeutic Effects of a Novel Small-Molecule Inhibitor of Inflammation in a Male C57BL/6J Mouse Model of Obesity-Induced NAFLD/MAFLD
McCall, K. D., Walter, D. L., Patton, A., Thuma, J. R., Courreges, M. C., Palczewski, G., Goetz, D. J., Bergmeier, S. C., & Schwartz, F. (2023) · Journal of Inflammation Research · doi:10.2147/jir.s413565 · Cited by 5
Nonalcoholic Fatty Liver Disease: Pharmacologic and Surgical Options
Parikh, N. D., & Ahmad, J. (2011) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2011.06.001 · Cited by 5
Metformin Use in Adolescents: Old and New Therapeutic Perspectives
Soliman, F. A. A. T. (2014) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000472 · Cited by 5
Validated Hptlc Method For Simultaneous Determination Of Metformin Hydrochloride And Glibenclamide In Combined Dosage Form
Malgundkar, M. S. S., & Mulla, S. (2014) · IOSR Journal of Pharmacy and Biological Sciences · doi:10.9790/3008-09255459 · Cited by 5
Nonviral Hepatitis
Wilbur, K. (2009) · Journal of Pharmacy Practice · doi:10.1177/0897190008328694 · Cited by 5
Hépatopathie non alcoolique: de la stéatose à la cirrhose
Leclercq, I. A., & Sempoux, C. L. (2006) · Acta Endoscopica · doi:10.1007/bf03006037 · Cited by 5
Treatment of fibrosis in nonalcoholic fatty liver disease
Hoteit, M. A., & Anania, F. A. (2007) · Current Gastroenterology Reports · doi:10.1007/s11894-008-0020-0 · Cited by 5
Les stéatopathies métaboliques : conséquences hépatiques du syndrome métabolique
Anty, R., Gual, P., Huet, P., MARCHAND‐BRUSTEL, Y. L., & Tran, A. (2007) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(07)78350-1 · Cited by 5
Stéatopathie métabolique : prise en charge
Pariente, A. E. (2009) · Gastroentérologie Clinique et Biologique · doi:10.1016/j.gcb.2009.02.028 · Cited by 5
Nonalcoholic fatty liver disease in children
Dahshan, A., Chalmers, L. J., & Tolia, V. K. (2008) · Therapy · doi:10.2217/14750708.6.1.83 · Cited by 4
Nonalcoholic fatty liver disease: a review
Poordad, F. F. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.3.661 · Cited by 4
Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease
Marzio, D. H., & Fenkel, J. M. (2014) · Advances in Hepatology · doi:10.1155/2014/357965 · Cited by 3
THE EFFECT OF MELATONIN, METFORMIN AND URSODEOXYCHOLIC ACID ON NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLINDED CONTROLLED TRIAL
Mojtahedi, K., Joukar, F., Fahim, S., Yeganeh, S., Asgharnezhad, M., Shafaghi, A., Asl, S. F., & Mansour‐Ghanaei, F. (2023) · Bulletin of Pharmaceutical Sciences Assiut · doi:10.21608/bfsa.2023.301123 · Cited by 3
Therapieoptionen für die nicht-alkoholinduzierte Fettleber und Fettleberhepatitis
Kluwe, J., & Lohse, A. W. (2005) · Der Internist · doi:10.1007/s00108-005-1513-7 · Cited by 3
Nonalcoholic fatty liver disease: treatment
Park, S. H. (2010) · The Korean Journal of Internal Medicine · Cited by 3
Tratamiento de la enfermedad hepática por depósito de grasa
Martín, M. C., Fernández-Gil, P. L., & Crespo, J. (2008) · Gastroenterología y Hepatología · doi:10.1157/13117902 · Cited by 3
A comparative study between metformin and insulin on biochemical variables in diabetic patients
Jasim, M. E., & Abdul-Razzaq, N. E. (2024) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2024.100206 · Cited by 2
Non-alcoholic Fatty Liver Disease in Obesity
Ferolla, S. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-19821-7_13 · Cited by 2
SIMULTANEOUS LC-MS/MS QUANTIFICATION METHOD FOR REMOGLIFLOZIN ETABONATE AND METFORMIN IN PLASMA SAMPLES: APPLICATION OF KINETIC STUDY IN RABBITS
Majumder, T., & Gubbiyappa, K. S. (2023) · RASAYAN Journal of Chemistry · doi:10.31788/rjc.2023.1628240 · Cited by 2
Mapping the global research landscape on nonalcoholic fatty liver disease and insulin resistance: A visualization and bibliometric study
Zyoud, S. H., Hegazi, O. E., Alalalmeh, S. O., Shakhshir, M. H., Abushamma, F., Khilfeh, S., & Al‐Jabi, S. W. (2024) · World Journal of Hepatology · doi:10.4254/wjh.v16.i6.951 · Cited by 2
Management of Cardiometabolic Complications in Patients With Nonalcoholic Fatty Liver Disease
Dennis, B. B., Sallam, S., Perumpail, B. J., Shah, N. D., Kim, D., Cholankeril, G. T., & Ahmed, A. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001555 · Cited by 2
Diabetes and Liver Disease
Meyer, D., & Bodenheimer, H. C. (2009) · Springer eBooks · doi:10.1007/978-0-387-09841-8_35 · Cited by 2
Non-Alcoholic Fatty Liver Disease
Bugianesi, E. (2009) · Frontiers of gastrointestinal research · doi:10.1159/000258249 · Cited by 2
Drug treatment and type 2 diabetes: the impact of liver disease
Ahmed, M., & Byrne, C. D. (2007) · Practical Diabetes · doi:10.1002/pdi.1132 · Cited by 2

Authors: Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P.
Affiliations: Ochsner Medical Center (US)
Johns Hopkins University (US)
Corresponding author: Nair, S.
ORCID: Nair, S.
Diehl, A. M.
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2004-06-14
Volume: 20
Issue: 1
Pages: 23-28
ISSN: 0269-2813 (ISSN-L)
1365-2036
DOI: 10.1111/j.1365-2036.2004.02025.x
OpenAlex: W2056505063
Cited by: 369
References: 37
Citations by year: 2026: 1 · 2025: 3 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 14 · 2017: 13 · 2016: 9 · 2015: 22 · 2014: 21 · 2013: 21 · 2012: 17
FWCI: 20.68
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords: metformin, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin sensitizers, insulin resistance, HOMA-IR, QUICKI, hepatic steatosis, liver fibrosis, liver inflammation, alanine aminotransferase, aspartate aminotransferase, drug safety and efficacy
MeSH terms: Alanine Transaminase, Aspartate Aminotransferases, Drug Evaluation, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Patient Compliance, Pilot Projects, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks